Peptide Library

GLP-1 receptor agonist with extensive Phase 3 trial data for type 2 diabetes and chronic weight management. Prescription-only in most jurisdictions.

Dual GIP / GLP-1 receptor agonist with strong Phase 3 evidence in type 2 diabetes (SURPASS) and obesity (SURMOUNT).

Eli Lilly's triple agonist (GLP-1 / GIP / glucagon receptor). Currently the most potent weight-management investigational drug — Phase 2 trials reported ~24% body weight reduction at the highest dose. Phase 3 TRIUMPH program ongoing. Not yet FDA-approved.

Daily GLP-1 receptor agonist (Saxenda/Victoza). FDA-approved for chronic weight management and type 2 diabetes. Older sibling of semaglutide with smaller weight-loss effect size.

Novo Nordisk's once-weekly combination of cagrilintide (an amylin analog) and semaglutide. Designed to combine appetite suppression (semaglutide) with satiety + meal-size regulation (cagrilintide). REDEFINE-1 Phase 3 showed ~22.7% weight loss at 68 weeks — strong but below pre-trial expectations.

Eli Lilly's once-daily ORAL non-peptide GLP-1 receptor agonist (LY3502970). The first oral small-molecule GLP-1 with no food/water restrictions (unlike Rybelsus). Phase 3 ACHIEVE program for diabetes and ATTAIN for obesity both ongoing.

GHRH analog (Egrifta) FDA-approved for HIV-associated lipodystrophy. Studied for visceral adiposity reduction outside that indication.

Boehringer Ingelheim / Zealand Pharma dual GLP-1 / glucagon receptor agonist (BI 456906). Strong Phase 2 obesity + MASH (liver) data. Phase 3 SYNCHRONIZE program ongoing across weight management, T2D, and liver disease indications.

Modified fragment (amino acids 176-191) of the C-terminus of human growth hormone. Originally developed by Metabolic Pharmaceuticals as an anti-obesity agent. Failed to meet Phase 2 primary endpoints for weight loss. Repurposed as a research / supplement-market compound; in some jurisdictions classified as a food supplement.

Synthetic peptide corresponding to amino acids 176-191 of human growth hormone. Stripped of growth-promoting and glucose-modulating effects (theoretically). Originally developed under the AOD-9604 program (see related entry). Marketed as a 'pure lipolytic' but human-trial evidence for clinically meaningful weight loss is weak.

Small-molecule NNMT inhibitor (NOT a peptide — it's a quinoline derivative). NNMT (nicotinamide N-methyltransferase) is upregulated in obese white adipose tissue. Preclinical studies show 5-Amino-1MQ reduces adipocyte size and improves metabolic markers in obese mice. No human RCTs. Sold as a research chemical.